NARCA: A novel prognostic scoring system using neutrophil‐albumin ratio and Ca19‐9 to predict overall survival in palliative pancreatic cancer
- 9 September 2018
- journal article
- research article
- Published by Wiley in Journal of Surgical Oncology
- Vol. 118 (4) , 680-686
Abstract
Background and Objectives: Several serum based‐markers and ratios have been investigated for their prognostic value in pancreatic ductal adenocarcinoma (PDAC). This cohort study aimed to combine these into a novel prognostic scoring system.Methods: A retrospective cohort study was performed on 145 patients with unresectable histologically‐confirmed PDAC. Based on the existing literature the following markers were investigated: neutrophil‐lymphocyte ratio (NLR), neutrophil‐albumin ratio (NAR), platelet‐lymphocyte ratio (PLR), fibrinogen, and Ca19‐9. These values were dichotomized about their medians for Kaplan‐Meier and Cox regression analysis.Results: Univariate Cox regression revealed statistically significant prognostic value for: NLR, NAR, PLR, fibrinogen, and Ca19‐9. When combining these using Cox regression analysis adjusting for other prognostic indicators, only NAR (hazard ratios [HR] = 3.174, P = 0.022) and Ca19‐9 (HR = 2.697, P = 0.031) were independent predictors of survival. Combining NAR and Ca19‐9 we split the cohort into three “NARCA” groups: NARCA0 = NAR ≤ 0.13 and Ca19‐9 ≤ 770, NARCA1 = either NAR > 0.13 or Ca19‐9 >770, NARCA2 = NAR > 0.13 and Ca19‐9 > 770. Median survival was 20.5, 9.7 and 4.1 months in NARCA0, 1, and 2 respectively ( P < 0.0005, log‐rank test). A separate validation cohort confirmed the prognostic significance of the score ( P = 0.048).Conclusions: Combining NAR and Ca19‐9 into a prognostic score allows stratification of unresectable PDAC patients into groups with significantly different overall survival.Keywords
This publication has 24 references indexed in Scilit:
- The pretreatment platelet and plasma fibrinogen level correlate with tumor progression and metastasis in patients with pancreatic cancerPlatelets, 2013
- The systemic inflammation-based Glasgow Prognostic Score: A decade of experience in patients with cancerCancer Treatment Reviews, 2013
- Exploiting inflammation for therapeutic gain in pancreatic cancerBritish Journal of Cancer, 2013
- Comparison of the prognostic values of various inflammation based factors in patients with pancreatic cancerMedical Oncology, 2012
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Serum CA 19-9 as a Biomarker for Pancreatic Cancer—A Comprehensive ReviewIndian Journal of Surgical Oncology, 2011
- Pancreatic CancerNew England Journal of Medicine, 2010
- CA 19-9 as a biomarker in advanced pancreatic cancer patients randomised to gemcitabine plus axitinib or gemcitabine aloneBritish Journal of Cancer, 2009
- Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinomaThe American Journal of Surgery, 2009
- Evaluation of an inflammation-based prognostic score in patients with inoperable pancreatic cancerPancreatology, 2006